Poll results: How comfortable are you with including biosimilars in your treatment plans?

Poll

See the results from our recent poll!

Optometry Times asked our audience, "How comfortable are you with including biosimilars in your treatment plans?" and the results are in!

The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 15 to Feb. 22, 2023.

10 ODs responded:

- 4 said, "Very excited to begin embracing biosimilars"

- 4 said, "Feeling comfortable exploring biosimilar options, though cautiously"

- 0 said, "Still hesitant, I need to learn more about biosimilars"

- 2 said, "With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans"

To learn more about biosimilars for AMD, check out Euin Cheong, OD's piece on "Introduction to biosimilars for AMD."

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
© 2025 MJH Life Sciences

All rights reserved.